P59.17 EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients
P. Walia(Princess Margaret Cancer Centre), G. Liu(Beijing Normal University), Natasha B. Leighl(Princess Margaret Cancer Centre), M. Chowdhury(Princess Margaret Cancer Centre), M. Catherine Brown(University Health Network), K. Khan(Health Net), Adrian G. Sacher(Princess Margaret Cancer Centre), D. Patel(Princess Margaret Cancer Centre), David Shultz(University of Toronto), Skye Hung‐Chun Cheng(Koo Foundation Sun Yat-Sen Cancer Center), Joshua Herman(University of Toronto), Amir Sabouhanian(Princess Margaret Cancer Centre), Luna Jia Zhan(University Health Network), Frances A. Shepherd(University Health Network), Severin Schmid(Health Net), Penelope A. Bradbury(University Health Network), Erik H. Strøm(University of Toronto), Miguel García-Pardo(Hospital Universitario Ramón y Cajal)
Cited by 3
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k